Browse EX-10 agreements

EXECUTION VERSION

AMENDMENT NO. 1 dated as of May 18, 2026 (this “Amendment”), by and among PACIFICORP, an Oregon corporation (the “Account Party”), the ISSUING BANKS party hereto and PNC BANK, NATIONAL ASSOCIATION, in its capacity as administrative agent (in such capacity, the “Administrative Agent”) under the Letter of Credit Agreement, dated as of April 3, 2026 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time prior to the date hereof, the “LC Agreement”; the Agreement, as amended by this Amendment, the “Amended LC Agreement), by and among the Account Party, the several Issuing Banks from time to time party thereto and the Administrative Agent. Capitalized terms used but not defined herein shall have the meanings assigned to such terms in the LC Agreement or the Amended LC Agreement, as applicable.

…

Execution Version

Certain identified information has been excluded from this exhibit because it is both not material and is the type of information that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”.

FOURTH AMENDMENT TO

THIRD AMENDED AND RESTATED CREDIT AGREEMENT

THIS FOURTH AMENDMENT TO THIRD AMENDED AND RESTATED CREDIT AGREEMENT(this “Amendment”), dated as of June 30, 2026 (the “Amendment Effective Date”), is by and among PACIFICORP, an Oregon corporation (the “Borrower”), the banks, financial institutions and other institutional lenders listed on the signature pages hereto (the “Lenders”), and JPMORGAN CHASE BANK, N.A., as administrative agent (in such capacity, the “Administrative Agent”)for the Lenders and the LC Issuing Banks. Capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed thereto in the Credit Agreement.

W I T N E S S E T H

…

​

Exhibit 10.1

EXECUTION VERSION

SECOND AMENDMENT TO CREDIT AGREEMENT

This SECOND AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is entered into as of August 4, 2026 among EL POLLO LOCO, INC., a Delaware corporation (the “Borrower”), the Guarantors party hereto, the Lenders party hereto and BANK OF AMERICA, N.A., as Administrative Agent. All capitalized terms used herein and not otherwise defined herein shall have the meanings given to such terms in the Credit Agreement (as defined below).

RECITALS

WHEREAS, the Borrower, the Guarantors, the Lenders and Bank of America, N.A., as Administrative Agent, Swingline Lender and L/C Issuer, have entered into that certain Credit Agreement dated as of July 27, 2022 (as amended, amended and restated, supplemented or otherwise modified from time to time, the “Credit Agreement”); and

WHEREAS, the Borrower has requested that the Lenders and the Administrative Agent amend the Credit Agreement on the terms and conditions more particularly set forth below.

…

Amendment No. 4 to Management Services Agreement

This Amendment No. 4 (this “Amendment”) to the Management Services Agreement, dated March 24, 2021, as amended on June 18, 2021, November 9, 2022 and May 12, 2023 (the “MSA”), is made this 7th day of August 2026, by and between Immix Biopharma, Inc., a Delaware corporation (the “Company”), and Alwaysraise, LLC, a California limited liability company (“Alwaysraise” and together with the Company, the “Parties”). Capitalized terms used in this Amendment but not defined herein have the meanings ascribed to them in the MSA.

WHEREAS, Gabriel Morris (“Mr. Morris”) is the sole principal of Alwaysraise;

WHEREAS, pursuant to the MSA, the Company engages Mr. Morris as the Company’s Chief Financial Officer; and 

WHEREAS, the Parties desire to amend the MSA as set forth herein.

NOW THEREFORE, in consideration of the premises and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree to amend the MSA as follows:

1. Amendments.

…

Amendment No. 3 to Employment Agreement

This Amendment No. 3 (the “Amendment”) to the Employment Agreement, dated June 18, 2021, as amended on November 9, 2022 and May 12, 2023 (the “Employment Agreement”), is made this 7th day of August 2026, by and between Immix Biopharma, Inc., a Delaware corporation (the “Company”), and Ilya Rachman (the “Executive” and together with the Company, the “Parties”). Capitalized terms used in this Amendment but not defined herein have the meanings ascribed to them in the Employment Agreement.

WHEREAS, the Parties desire to amend the Employment Agreement as set forth herein.

NOW THEREFORE, in consideration of the premises and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree to amend the Employment Agreement as follows:

1. Amendments.

1.1 Section 3.1 of Section 3 “Compensation and Benefits” is hereby deleted in its entirety and replaced with the following:

…

MASTER Services AGREEMENT

This MASTER SERVICES AGREEMENT (this “Agreement”), dated as of May 20, 2026 (the “Effective Date”), is by and between ARK Capital Markets LLC, a Texas limited liability company (“ARK”), and Eightco Holdings Inc., a Texas corporation (NASDAQ: ORBS) (the “Company”).

WHEREAS, pursuant to that certain Letter of Intent / Term Sheet, dated March 8, 2026, by and between ARK and the Company, ARK agreed to enter into an agreement to provide certain services to the Company on the terms and conditions set forth therein; and

WHEREAS, the Company desires to enter into this Agreement to retain ARK to render, and ARK desires to provide, certain services, on the terms and conditions set forth herein.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound hereby, the parties agree as follows:

ARTICLE I

** **

APPOINTMENT AND COMPENSATION

** **

Section 1.1 – Appointment

** **

…

Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private or confidential, including the identity and designation of the licensed antibody and its molecular target. Such omissions are marked with [***]. In addition, certain schedules and exhibits to this agreement have been omitted pursuant to Item 601(a)(5) of Regulation S-K; the registrant hereby undertakes to furnish supplementally a copy of any omitted schedule or exhibit to the Securities and Exchange Commission upon request.

LICENSE AGREEMENT

…

Consulting Agreement

Louise Walker

This consulting agreement is entered into between First Northern Bank (“Client) and Louise Walker (“Consultant”) as of February 17, 2026.

BACKGROUND

	A.	The Client is of the opinion that the Consultant has the necessary qualifications, experience and abilities to provide consulting services to the Client.

…

May 6, 2026

Dana Perez

Via e-mail:

Dear Dana:

On behalf of SharpLink, Inc. (the “Company”), I am pleased to inform you that the Board of Directors has appointed you as Chief Accounting Officer on the following terms:

| | |

…

INDIE SEMICONDUCTOR, INC.

2021 OMNIBUS EQUITY INCENTIVE PLAN

ARTICLE I

PURPOSE

The purpose of this indie Semiconductor, Inc. 2021 Omnibus Equity Incentive Plan (the “Plan”) is to benefit indie Semiconductor, Inc., a Delaware corporation (the “Company”) and its stockholders, by assisting the Company and its subsidiaries to attract, retain and provide incentives to key management employees, directors, and consultants of the Company and its Affiliates, and to align the interests of such service providers with those of the Company’s stockholders. Accordingly, the Plan provides for the granting of Non-qualified Stock Options, Incentive Stock Options, Restricted Stock Awards, Restricted Stock Unit Awards, Stock Appreciation Rights, Performance Stock Awards, Performance Unit Awards, Unrestricted Stock Awards, Distribution Equivalent Rights or any combination of the foregoing.

ARTICLE II

DEFINITIONS

The following definitions shall be applicable throughout the Plan unless the context otherwise requires:

2.1

…

CERTAIN INFORMATION IDENTIFIED BY BRACKETED ASTERISKS ([***]) HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

** **

July 31, 2026

Via Federal Express

Maxim Group LLC

300 Park Avenue, 16th Floor

New York, New York 10022,

Attention: Clifford A. Teller and James Siegel

	Re:	Mutual Termination of Controlled Equity Distribution Agreement

To Whom It May Concern:

Reference is made to the Equity Distribution Agreement (the “Agreement”), dated as of April 1, 2023, by and among Aim ImmunoTech Inc., a Delaware corporation (“Company”), and Maxim Group LLC, as sales agent and/or principal (the “Agent”).

…

Exhibit 10.2 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of August 5, 2026 between and among Banc of California, Inc. (the “Company”), Banc of California, a California state-chartered bank (the “Bank” and together with the Company, “Employer”), on the one hand, and Joseph Kauder (“Executive”), on the other hand. WHEREAS, Employer and Executive entered into an Employment Agreement dated July 5, 2023 (the “Prior Agreement”); WHEREAS, Employer desires to continue to employ Executive, and Executive desires to continue to be employed by Employer upon the terms and subject to the conditions set forth in this Agreement, effective as of the Effective Date (as defined below); and WHEREAS, the Employer and Executive are entering into this Agreement to amend and restate the Prior Agreement. NOW, THEREFORE, in consideration of the premises and mutual covenants contained in this Agreement, the parties agree as follows: 1. Employment. Employer agrees to continue to employ Executive, and Executive accepts continued e

…